Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma Background <p>Glioblastoma (GBM) is an aggressive brain tumor associated with poor outcome and limited treatment options. Chimeric antigen receptor (CAR) T cells targeting cell surface antigens were shown to induce tumor regression in patients with GBM, although efficacy was transient. To broaden the range of tumor-restricted antigens, we developed CAR T cells targeting Tenascin-C (TNC), a secreted extracellular matrix protein… Journal for ImmunoTherapy of Cancer November 7, 2025 Original source
Association between prostatic inflammation and detrusor overactivity in men with benign prostatic hyperplasia and bladder outlet obstruction: a prospective urodynamic and histological study <p>Prostate Cancer and Prostatic Diseases, Published online: 29 October 2025; <a href="https://www.nature.com/articles/s41391-025-01039-7">doi:10.1038/s41391-025-01039-7</a></p>Association between prostatic inflammation and detrusor overactivity in men with benign prostatic hyperplasia and bladder outlet obstruction: a prospective urodynamic and histological study Prostate Cancer Journal November 7, 2025 Original source
Imaging in focal therapy: advanced ultrasound imaging and mpMRI—a comprehensive review <p>Prostate Cancer and Prostatic Diseases, Published online: 30 October 2025; <a href="https://www.nature.com/articles/s41391-025-01017-z">doi:10.1038/s41391-025-01017-z</a></p>Imaging in focal therapy: advanced ultrasound imaging and mpMRI—a comprehensive review Prostate Cancer Journal November 7, 2025 Original source
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis <p>Prostate Cancer and Prostatic Diseases, Published online: 01 November 2025; <a href="https://www.nature.com/articles/s41391-025-01047-7">doi:10.1038/s41391-025-01047-7</a></p>DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis Prostate Cancer Journal November 7, 2025 Original source
Methodological concerns regarding KEYNOTE-199: immortal time bias and treatment attribution challenges in combination immunotherapy <p>Prostate Cancer and Prostatic Diseases, Published online: 03 November 2025; <a href="https://www.nature.com/articles/s41391-025-01051-x">doi:10.1038/s41391-025-01051-x</a></p>Methodological concerns regarding KEYNOTE-199: immortal time bias and treatment attribution challenges in combination immunotherapy Prostate Cancer Journal November 7, 2025 Original source
Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes <p>Prostate Cancer and Prostatic Diseases, Published online: 04 November 2025; <a href="https://www.nature.com/articles/s41391-025-01050-y">doi:10.1038/s41391-025-01050-y</a></p>Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes Prostate Cancer Journal November 7, 2025 Original source
High level expression of glucocorticoid receptor (GR) is linked to aggressive tumor features, early biochemical recurrence, and genetic instability in prostate cancer <p>Prostate Cancer and Prostatic Diseases, Published online: 05 November 2025; <a href="https://www.nature.com/articles/s41391-025-01046-8">doi:10.1038/s41391-025-01046-8</a></p>High level expression of glucocorticoid receptor (GR) is linked to aggressive tumor features, early biochemical recurrence, and genetic instability in prostate cancer Prostate Cancer Journal November 7, 2025 Original source
Primary MRI versus PSA-gated scans in Prostate Cancer Screening – how ready is it for mainstream implementation? <p>Prostate Cancer and Prostatic Diseases, Published online: 06 November 2025; <a href="https://www.nature.com/articles/s41391-025-01048-6">doi:10.1038/s41391-025-01048-6</a></p>Primary MRI versus PSA-gated scans in Prostate Cancer Screening – how ready is it for mainstream implementation? Prostate Cancer Journal November 7, 2025 Original source
A randomized controlled trial comparing en-bloc vs lobe-by-lobe HoLEP: surgical efficiency and early continence outcomes <p>Prostate Cancer and Prostatic Diseases, Published online: 06 November 2025; <a href="https://www.nature.com/articles/s41391-025-01040-0">doi:10.1038/s41391-025-01040-0</a></p>A randomized controlled trial comparing en-bloc vs lobe-by-lobe HoLEP: surgical efficiency and early continence outcomes Prostate Cancer Journal November 7, 2025 Original source
CRISPR/Cas9-mediated t(4;11) translocation in human hematopoietic stem/precursor cells demonstrates plasticity to differentiate into either the myeloid or lymphoid lineage <p>Leukemia, Published online: 27 October 2025; <a href="https://www.nature.com/articles/s41375-025-02791-4">doi:10.1038/s41375-025-02791-4</a></p>CRISPR/Cas9-mediated t(4;11) translocation in human hematopoietic stem/precursor cells demonstrates plasticity to differentiate into either the myeloid or lymphoid lineage Leukemia Journal November 7, 2025 Original source
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients <p>Leukemia, Published online: 27 October 2025; <a href="https://www.nature.com/articles/s41375-025-02781-6">doi:10.1038/s41375-025-02781-6</a></p>Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients Leukemia Journal November 7, 2025 Original source
Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia <p>Leukemia, Published online: 27 October 2025; <a href="https://www.nature.com/articles/s41375-025-02764-7">doi:10.1038/s41375-025-02764-7</a></p>Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia Leukemia Journal November 7, 2025 Original source
Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study <p>Leukemia, Published online: 27 October 2025; <a href="https://www.nature.com/articles/s41375-025-02789-y">doi:10.1038/s41375-025-02789-y</a></p>Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study Leukemia Journal November 7, 2025 Original source
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial <p>Leukemia, Published online: 03 November 2025; <a href="https://www.nature.com/articles/s41375-025-02787-0">doi:10.1038/s41375-025-02787-0</a></p>Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial Leukemia Journal November 7, 2025 Original source
<i>asxl1</i> C-terminal truncation and <i>SRSF2</i> mutation drive leukemogenesis via immune reprogramming <p>Leukemia, Published online: 03 November 2025; <a href="https://www.nature.com/articles/s41375-025-02790-5">doi:10.1038/s41375-025-02790-5</a></p><i>asxl1</i> C-terminal truncation and <i>SRSF2</i> mutation drive leukemogenesis via immune reprogramming Leukemia Journal November 7, 2025 Original source
Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib <p>Leukemia, Published online: 03 November 2025; <a href="https://www.nature.com/articles/s41375-025-02793-2">doi:10.1038/s41375-025-02793-2</a></p>Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib Leukemia Journal November 7, 2025 Original source
In memoriam: Malcom A.S. Moore (1944–2025) <p>Leukemia, Published online: 06 November 2025; <a href="https://www.nature.com/articles/s41375-025-02806-0">doi:10.1038/s41375-025-02806-0</a></p>In memoriam: Malcom A.S. Moore (1944–2025) Leukemia Journal November 7, 2025 Original source
On FFMI as a Proxy for Muscle Mass, or How Redundancy and Multicollinearity Distort Inference . <br /> Nutrition and Cancer Journal November 7, 2025 Original source
GLR in Cholangiocarcinoma: A Practical Biomarker in Need of Validation . <br /> Nutrition and Cancer Journal November 7, 2025 Original source
Nutrition Screening and Assessment Tools for Adult Patients with Cancer and Survivors of Cancer: A Systematic Review . <br /> Nutrition and Cancer Journal November 7, 2025 Original source